Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium

Biochemical Pharmacology

Volumn 92, Issue 3, 2014, Pages 476-483

  Delacour, Herve ^a   Lushchekina, Sofya ^b   Mabboux, Isabelle ^a   Ceppa, Franck ^a   Masson, Patrick ^c,d   Schopfer, Lawrence M ^d   Lockridge, Oksana ^d  

^a Military Teaching Hospital Begin   (France)

^b EMANUEL INSTITUTE OF BIOCHEMICAL PHYSICS   (Russian Federation)

^c KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Butyrylcholinesterase deficiency; Genetic diagnosis

Indexed keywords

BENZOYLCHOLINE; BUTYRYLTHIOCHOLINE; CHOLINESTERASE; CINCHOCAINE; FLUORIDE; GENOMIC DNA; MIVACURIUM; SUCCINYLDITHIOCHOLINE; SUXAMETHONIUM; UNCLASSIFIED DRUG; CHOLINESTERASE INHIBITOR; ISOQUINOLINE DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

AGED; ARTICLE; BLOOD SAMPLING; BUTYRYLCHOLINESTERASE DEFICIENCY; CASE REPORT; CATALYSIS; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME KINETICS; EXON; FEMALE; GENETIC CONSERVATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYDROGEN BOND; HYDROLYSIS; INHIBITION CONSTANT; MALE; MENISCAL SURGERY; MISSENSE MUTATION; MOLECULAR DIAGNOSIS; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NEUROMUSCULAR BLOCKING; PHENOTYPE; POINT MUTATION; SIMULATION; SINGLE DRUG DOSE; STEADY STATE; CHEMISTRY; GENETICS; HETEROZYGOTE; METABOLISM; PEDIGREE;

AGED; BUTYRYLCHOLINESTERASE; BUTYRYLTHIOCHOLINE; CHOLINESTERASE INHIBITORS; FEMALE; HETEROZYGOTE; HUMANS; ISOQUINOLINES; MALE; MOLECULAR DYNAMICS SIMULATION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PEDIGREE; POINT MUTATION; SUCCINYLCHOLINE;

EID: 84910642392     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.09.014     Document Type: Article

References (28)

1. Masson P, Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behaviour. Arch Biochem Biophys 2010;494:107-20.
2. Johnson G, Moore SW. Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene. Neurochem Int 2012;61:783-97.
3. Forbat A, Lehmann H, Silk E. Prolonged apnea following injection of succinylcholine. Lancet 1953;265:1067-8.
4. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine number. Can J Biochem Physiol 1957;35:339-46.
5. Souza RL, Mikami LR, Maegawa RO, Chautard-Freire-Maia EA. Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample. Mol Genet Metab 2005;84:349-53.
6. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
7. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
8. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010;7:575-6.
9. Harris H, Whittaker M. Differential inhibition of human serum cholinesterase with fluoride: recognition of two new phenotypes. Nature 1961;191:556-62.
10. Cook DR, Stiller RL, Neal Wealky J, Chakravorti S, Brandom BW, Welch RM. In vitro metabolism of mivacurium (BW B1090U) and succinylcholine. Anesth Analg 1989;68:452-6.
11. Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 1974;137:143-4.
12. Radić Z, Pickering NA, Vellom DC, Camp S, Taylor P. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993;32:12074-84.
13. Masson P, Legrand P, Bartels CF, Froment MT, Schopfer LM, Lockridge O. Role of aspartate 70 and tryptophane 82 in binding of succinyldithiocholine to human butyrylcholinesterase. Biochemistry 1997;36:2266-77.
14. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003;278:41141-47.
15. Masson P, Lushchekina S, Schopfer LM, Lockridge O. Effects of viscosity and osmotic stress on the reaction of human butyrylcholinesterase with cresyl saligenin phosphate, a toxicant related to the aerotoxic syndrome: kinetic and molecular dynamics studies. Biochem J 2013;454:387-99.
16. Lushchekina SV, Nemukhin AV, Varfolomeev SD, Masson P. Molecular modeling evidence for His 438 flip in the mechanism of BuChE hysteretic behavior. J Mol Neurosci 2014;52:434-45.
17. Delacour H, Lushchekina S, Mabboux I, Bousquet A, Ceppa F, Schopfer LM, et al. Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium. PLoS One 2014;9(7):e101552.
18. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781-802.
19. Best RB, Zhu X, Shim J, Lopes PEM, Mittal J, Feig M, et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ1 and χ2 dihedral angles. J Chem Theor Comput 2012;8:3257-73.
20. Sadovnichy V, Tikhonravov A, Voevodin V, Opanasenko V. Lomonosov: supercomputing at Moscow State University. In: Vetter JS, editor. Contemporary high performance computing: from petascale toward exascale. Boca Raton, USA: CRC Press; 2013. p. 283-307.
21. Bakan A, Meireles LM, Bahar I. ProDy: protein dynamics inferred from theory and experiments. Bioinformatics 2011;27:1575-7.
22. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33-8.
23. Bartels CF, James K, La Du BN. DNA mutations associated with the human butyrylcholinesterase gene. Am J Hum Genet 1992;50:1104-14.
24. Primo-Parmo SL, Bartels CF, Wiersema B, Van der Spek AFL, Innis JW, La Du BN. Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Am J Hum Genet 1996;58:52-64.
25. Masson P, Xie W, Froment MT, Lockridge O. Effects of mutations of active site residues and amino acids interacting with the V loop on substrate activation. Biochim Biophys Acta 2001;1544:166-76.
26. Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther 1990;47:35-60.
27. Lockridge O, Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. NeuroToxicology 2000;21:113-26.
28. Manoharan I, Boopathy R, Darvesh S, Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta 2007;378:128-35.